Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South KoreaArticle Published on 2022-09-232022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] baseline BNT BNT162b2 ChAdOx1 cohort study collected comparable conducted convalescent COVID-19 patients convalescent sera correlation COVID-19 COVID-19 pandemic COVID-19 vaccination cumulative Decreased Delta delta variant dose estimation explain groups HCW HCWs healthcare worker Heterologous highest homologous IQR Kinetics median Neutralizing neutralizing antibody Neutralizing antibody titer outbreak performed PRNT Protective protective immunity protocol SARS-CoV-2 sera serum sample significantly higher South Korea the mean vaccination vaccination. Vaccine development variants of concern VoC VOCs was used wild type wild-type SARS-CoV-2 WT SARS-CoV-2 [DOI] 10.3389/fimmu.2022.968105 PMC 바로가기
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19Article Published on 2022-09-172022-11-15 Journal: Nature Communications [Category] SARS, 변종, 진단, [키워드] 1:1 95% CI assigned booster dose ChAdOx1 ChAdOx1 nCoV-19 COVID-19 COVID-19 vaccine delta variant facilitate first dose geometric mean titer GMT ratio groups healthy Heterologous heterologous prime-boost immunization neutralizing antibody Neutralizing antibody titer non-inferiority trial occurred outcome prime-boost interval Randomized Randomized controlled trial Randomly receive recipient reported Serious Adverse Event subunit subunit vaccines Support T cell response Vaccine Viral vector vaccine wild-type SARS-CoV-2 [DOI] 10.1038/s41467-022-33146-7 PMC 바로가기
Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipientsArticle Published on 2022-09-162022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] acute respiratory syndrome Administered adverse effect analyzed Anti-spike antibody BNT162b2 cellular cellular response Cellular responses ChAdOx1 Characteristics coronavirus creatinine Efficacy elicited first dose highest humoral immunogenicity interferon-γ kidney kidney transplant mRNA mRNA1273 Patient patients platform positive Protein Protein subunit recipient rejection renal function SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose the patient the spike protein vaccination Vaccination strategy Vaccine Vaccines Vaccines. Viral vector [DOI] 10.3389/fimmu.2022.951576 PMC 바로가기
Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipientsArticle Published on 2022-09-092022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] Abbott Diagnostics Ad5-nCoV Analysis analyzed applied blood sample BNT162b2 BNT162b2 vaccine ChAdOx1 China Comorbidity Complete Control controls CoronaVac COVID-19 COVID-19 vaccine DiaSorin Efficacy evaluate Gam-COVID-Vac healthy healthy controls humoral Humoral response IgG immunosuppressants Italy life liver median Mexico mRNA-1273 multivariable model Oxford-AstraZeneca Pandemia participant Patient patients Pfizer-BioNTech platform positive Prednisone recipient recipients reduced SARS-CoV-2 vaccine Serologic response serological response Sinovac USA vaccination Vaccine vaccine doses Vaccines. women [DOI] 10.1016/j.vaccine.2022.08.027 PMC 바로가기
Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down SyndromeObservational Study Published on 2022-09-042022-10-05 Journal: The Journal of Infectious Diseases [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome age antibody concentration Antibody Response antibody response. BNT162b2 ChAdOx1 clinical coronavirus coronavirus 2 Course COVID-19 COVID-19 vaccination Decreased Down syndrome healthy control higher risk increase in increasing age Infection Messenger RNA Mortality mRNA mRNA vaccination prospective observational cohort respiratory response resulting risk SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 vaccination Trial Vaccinations [DOI] 10.1093/infdis/jiac235 PMC 바로가기 [Article Type] Observational Study
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular InvestigationArticle Published on 2022-08-302022-11-15 Journal: Viruses [Category] SARS, 진단, [키워드] activated acute respiratory syndrome antibody Antibody Response caused CD4+ naïve Cell cellular Cellular and humoral immunity cellular response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 COVID-19 group D-dimer level DAV death effective faster humoral Humoral immunity hybrid immunity. IFN-γ IgG immune response Immunity increase in individual individuals induce infected individual interferon-γ investigated investigation Lymphocytes memory memory B cells naïve neutralizing antibody positive correlation SARS-CoV-2 SARS-CoV-2 vaccine secretion significant difference Support triggered vaccinated individual vaccination Vaccine with COVID-19 [DOI] 10.3390/v14091916 PMC 바로가기
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana projectArticle Published on 2022-08-292022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] adverse event age and sex analyzed anti-SARS-CoV-2 baseline Biomarker booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine chemiluminescence chemokines Concentration Controlled trial COVID-19 Cytokines death dose effective Effectiveness evaluated exclusion first dose Fractional dose Frequency geometric mean Growth factors healthcare worker Hospitalization immune response immunization immunoassay immunogenic immunogenicity incidence incidence rate increase in indicate individual individuals multiplex neutralizing antibody non-inferiority non-randomized plaque reduction neutralization plasma pre-immune primary endpoint PRNT Protein quantified RBD Receptor binding domain Registered reported RT-PCR Safe Safety second dose Serious Adverse Event seroconversion rate seronegative seropositive seropositive subject SUS Vaccine vaccine. Vaccines [DOI] 10.3389/fimmu.2022.966416 PMC 바로가기
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older peopleResearch article Published on 2022-08-252022-10-05 Journal: Cell Reports Medicine [Category] 변종, [키워드] adenoviral vector age antibody Antibody titer baseline BNT162b2 booster cellular immunity cellular response ChAdOx1 COVID-19 COVID-19 mortality COVID-19 vaccine determine develop Donor dose elderly elicit extended interval humoral Immunity immunogenic mRNA neutralization Older omicron peak Primary series regimen retained standard interval sustained vaccination vaccine immunogenicity Vaccines variant [DOI] 10.1016/j.xcrm.2022.100739 [Article Type] Research article
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses중증 급성 호흡기 증후군 코로나바이러스 2 백신 접종은 계절성 인간 코로나바이러스에 대한 중화 활성을 향상시킵니다Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 치료법, [키워드] 229E activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against analyzed average BNT162b2 causative agent ChAdOx1 ChAdOx1 nCoV-19 circulating colds common cold Concentration coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccinations cross-neutralization cross-protection determined by Efficiency Endemic Gene Expression HCoV HCoV-229E HCoV-NL63 HCoV-OC43 HCoVs Heterologous Huh-7 cells Human human coronavirus incubated individual inhibitory activity MERS MERS-CoV Middle East Middle East respiratory syndrome MOST neutralization neutralize Neutralizing activity NL63 nucleocapsid expression OC43 Preexisting immunity pseudoparticle pseudovirion pseudovirions reporter reporter gene respiratory SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 vaccination seasonal seasonal coronavirus seasonal coronaviruses seasonal coronaviruses. sera severe acute respiratory syndrome Coronavirus significantly increased Spike proteins these viruses vaccination Viral RNA virus [DOI] 10.1093/cid/ciac057 PMC 바로가기 [Article Type] Article
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohortVirus Watch 코호트의 SARS-CoV-2 항체 및 획기적인 감염Article Published on 2022-08-182022-09-12 Journal: Nature Communications [Category] SARS, 진단, [키워드] 95% confidence interval anti-S anti-S antibody antibody BNT162b2 booster vaccination Breakthrough infection ChAdOx1 clinically Cohort Course Delta Effectiveness Efficacy Evidence geometric hazard higher risk Increasing individual Infection nine Older protective effect provide Ratio reduced risk risk risk of infection SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 vaccine second dose Support the timing total effect Vaccine [DOI] 10.1038/s41467-022-32265-5 PMC 바로가기 [Article Type] Article